Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
NCT ID: NCT03486067
Last Updated: 2025-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
183 participants
INTERVENTIONAL
2018-04-03
2025-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
NCT04036461
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03266692
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT03489525
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of CC-93269
CC-93269
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-93269
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Must have measurable disease as determined by the central laboratory
Exclusion Criteria
* Prior autologous stem cell transplant ≤ 3 months prior
* Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
* History of concurrent second cancers requiring active, ongoing systemic treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 105
Birmingham, Alabama, United States
Local Institution - 103
San Francisco, California, United States
Local Institution - 107
New Haven, Connecticut, United States
Local Institution - 106
Atlanta, Georgia, United States
Local Institution - 109
Boston, Massachusetts, United States
Local Institution - 111
Boston, Massachusetts, United States
Henry Ford Medical Center - New Center One
Detroit, Michigan, United States
Icahn School of Medicine at Mount Sinai Mount Sinai West
New York, New York, United States
Local Institution - 101
Seattle, Washington, United States
Local Institution - 305
Erlangen, , Germany
Local Institution - 303
Hamburg, , Germany
Local Institution - 302
Heidelberg, , Germany
Local Institution - 306
München, , Germany
Local Institution - 304
Tübingen, , Germany
Local Institution - 402
Bergamo, , Italy
Local Institution - 403
Meldola, , Italy
Local Institution - 401
Milan, , Italy
Local Institution - 602
Nagoya, Aichi-ken, Japan
Local Institution - 603
Shibuya-ku, Tokyo, Japan
Local Institution - 605
Kamakura, , Japan
Local Institution - 604
Kashiwa, , Japan
Local Institution - 601
Kyoto, , Japan
Local Institution - 206
Barcelona, , Spain
Local Institution - 208
Barcelona, , Spain
Local Institution - 205
Madrid, , Spain
Local Institution - 201
Pamplona, , Spain
Local Institution - 203
Salamanca, , Spain
Local Institution - 204
Santander, , Spain
Local Institution - 207
Valencia, , Spain
Local Institution - 202
Valencia, , Spain
Local Institution - 504
Gothenborg, , Sweden
Local Institution - 502
Lund, , Sweden
Local Institution - 501
Stockholm, , Sweden
Local Institution - 505
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1210-6325
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-506564-14
Identifier Type: OTHER
Identifier Source: secondary_id
CC-93269-MM-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.